Neurogene Inc. (NGNE) - Comprehensive Overview
Key Finding: Neurogene Inc. (NGNE) is a clinical-stage biotech company advancing gene therapies for rare neurological diseases like Rett syndrome, with recent positive trial data and a $125M financing driving strong stock gains amid high volatility typical of the sector.
Company Overview
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare and devastating neurological diseases using its proprietary EXACT™ transgene regulation technology.
Company History
Founded in 2018 (some sources reference earlier origins around 2007, possibly due to predecessor entities or rebranding), Neurogene has focused on gene therapy for neurological conditions from inception.
- Developed proprietary EXACT platform for controlled transgene expression.
- Advanced lead candidate NGN-401 into clinical trials for Rett syndrome.
- Secured licensing agreements with institutions including University of Edinburgh, Stanford, and others.
- Went public on NASDAQ under ticker NGNE (details of IPO or listing not specified in sources; post-2018 development).
The company's history reflects a targeted build-out in the competitive gene therapy space, with emphasis on rare disease unmet needs.
Product Pipeline
| Candidate |
Indication |
Stage |
Notes |
| NGN-401 |
Rett syndrome |
Phase 1/2 (Embolden registrational trial) |
AAV9-packaged; positive long-term data reported; dosing nearly complete in key trial |
| NGN-101 |
CLN5 Batten disease |
Phase 1/2 |
Conventional AAV9 gene therapy delivering CLN5 gene |
Pipeline focuses on high-unmet-need rare neurological diseases.
Recent News (as of July 2026)
- July 2026: Announced positive long-term clinical data from Phase 1/2 trial of NGN-401 for Rett syndrome.
- July 1, 2026: Priced $125 million public offering.
- June 30, 2026: Proposed public offering announced.
- July 6, 2026: Inducement grants under Nasdaq rules.
- Successful completion of dosing in Embolden registrational trial for NGN-401.
These events, particularly the financing and positive data, likely contributed to recent stock momentum.
Stock Performance
Data as of approximately July 8-10, 2026 (snapshot from multiple sources; prices fluctuate intraday).
| Metric |
Value |
| Recent Close |
~$38.24 (July 8); ranged $36.80–$42.84 recently |
| 52-Week Range |
$15.93 – $43.66 |
| Market Cap |
~$700M – $860M |
| YTD Return |
~108% |
| 1-Year Return |
~101% |
| Analyst Target (1y Est.) |
~$81.71 |
| EPS (Recent Q1 2026) |
-$1.39 (missed estimates) |
Links for more information:
The stock has shown significant outperformance versus broader markets (e.g., S&P 500), consistent with biotech catalysts like trial data and financings, but remains highly volatile.
Data Limitations and Assumptions
- Stock prices, market cap, and returns are time-sensitive snapshots from web sources as of ~July 9-10, 2026; real-time values differ.
- Company founding date shows minor discrepancies (primarily 2018 vs. occasional 2007 references); primary sources indicate 2018.
- Clinical trial outcomes are uncertain and subject to regulatory approval; positive data does not guarantee success.
- Earnings misses and biotech risks (dilution from offerings, no revenue) are standard uncertainties.
- No forward-looking financial projections or guarantees provided; past performance ≠ future results.
- Sources primarily from financial aggregators and company releases; independent verification recommended.
Distinction: All pipeline, financial metrics, and news items above are presented as reported facts from sources. Interpretations (e.g., catalyst impact) are clearly labeled as such.